The current principles of management in acute kidney injury (AKI) rely on the almost century-old gold standard of serum creatinine, which may be both delayed and nonspecific. Novel biomarkers that signal renal damage may be able to reform disease detection and management for perioperative AKI. Of the many potential candidates, interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty-acid-binding protein (L-FABP), and cystatin C are at the forefront of clinical validation. Notably, these molecules can detect cases of subclinical AKI, which traditional measures may fail to identify, and may offer an opportunity for early treatment of AKI while providing valuable prognostic information. Though there is still progress to be made, the application of these biomarkers and the significant clinical changes they will bring about may be on the horizon.
|Original language||English (US)|
|Title of host publication||Perioperative Kidney Injury|
|Subtitle of host publication||Principles of Risk Assessment, Diagnosis and Treatment|
|Publisher||Springer New York|
|Number of pages||12|
|State||Published - Jan 1 2015|
ASJC Scopus subject areas